The NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome has emerged as a critical mediator in cardiovascular diseases, connecting cholesterol crystals and metabolic danger signals to atherogenic inflammation, myocardial injury, and adverse remodeling. Using direct inhibitors that bind to NLRP3 has advantages over indirect strategies. These advantages include retaining the function of other inflammatory body sensors and the potential for oral treatment. Several synthetic compo